Background: The genetic component of Crohn's disease (CD) is well known, with 140 susceptibility loci identified so far. In addition to single nucleotide polymorphisms typically studied in genome-wide scans, copy number variation is responsible for a large proportion of human genetic variation.
and weight loss, and it has important social consequences. CD is a heterogeneous disorder with differences in disease location, behavior, and age of onset. The cause of IBD is multifactorial-environmental and genetic-and poorly understood. 2 The current hypothesis is that of an exaggerated mucosal immune response to the gut microbiota in a genetically susceptible host. Genome-wide association studies and subsequent meta-analyses identified a total of 140 CD susceptibility loci so far. [3] [4] [5] [6] The most strongly associated genes are NOD2 and IL23R, both involved in innate immunity and bacterial sensing; ATG16L1 is an essential autophagy gene, and PTGER4 is involved in epithelial restitution. 6 A strong association was also found to the major histocompatibility complex (MHC). 6, 7 The MHC region is characterized by a very high gene density and genetic variation, and strong and long-range linkage disequilibrium, spanning over 3.6 Mb. This makes it difficult to identify which gene or genes are most relevant in the context of disease association. The region encodes a set of cell surface molecules also called the human leukocyte antigens (HLA) that present peptide antigens to the immune system. 8 There are 2 major classes of MHC molecules: class I and class II. Other genes that map within the MHC (MHC class III) include complement components (complement component C2, complement component C4, and factor B) and cytokines (tumor necrosis factor-a and lymphotoxin [LTA, LTB] ).
In addition to single-nucleotide polymorphisms (SNPs) typically studied in genome-wide association studies, copy number variation (CNV) is responsible for a large proportion of human genetic variation. 9 Several CNVs contribute to susceptibility to (auto)immune and inflammatory disorders. [10] [11] [12] Associations of CNV to CD have been reported: a deletion polymorphism in the promoter region of the IRGM gene is associated with altered IRGM expression and with CD. 13 A genomewide CNV association study replicated the IRGM deletion and found 2 additional CNVs: a not further fine-mapped CNV in the MHC region and a 900-kb inversion polymorphism on chromosome 17 (CNVR7113.6). 14 To identify chromosomal areas of CNV associated with CD, we performed an exploratory genome-wide CNV analysis by array comparative genomic hybridization (aCGH) using an in-house developed 32K bacterial artificial chromosome (BAC) array. We identified several regions that vary in copy number in individuals with CD and further focused on 1 such region on chromosome 6p21 in the central MHC region through independent validation and functional follow-up.
MATERIALS AND METHODS

Development of a CNV-Specific BAC Array
Different platforms to detect CNVs have been developed and commercialized: clone (typically BACs but cosmids or complementary DNAs are also used) or oligonucleotide-based arrays that can only detect copy number variants and arrays interrogating both SNPs and CNVs. Each of these platforms has advantages and disadvantages for the study of CNVs. In the comprehensive study by Redon et al, 9 it was shown that both BAC-based arrays and the 500K Affymetrix SNP chip (Affymetrix, Santa Clara, CA) detect CNVs. However, only 30% of all CNVs overlapped, indicating that both platforms detect different types of CNVs. One reason is that complex genomic regions are selected against in oligonucleotide-based arrays (including the SNP arrays). Another reason may be the nature of the clones: stretches of 150 kb detect different genomic rearrangements as compared with small oligonucleotides. Because of our experience with BAC arrays, the observation that the larger CNVs are better detected using BAC arrays, and our knowledge about the sensitivity to detect mosaicism using BAC arrays (see below), we used BAC arrays. A CNV BAC array was developed in house containing 3906 clones. Clones were chosen to overlap with known copy number variable regions as reported in the study by Redon et al 9 and based on the database of genomic variants (http://projects.tcag.ca/variation/). Three thousand five hundred four clones were annotated in the database of genomic variants, and 156 overlapped with the most frequent polymorphic regions as described by Redon et al. 9 Five hundred forty BAC clones located in non-copy number variable regions were used for internal normalization. The majority of the BAC clones (n ¼ 3210) came from the Children's hospital Oakland Research Institute, where the "BACPAC Resource Center" is located. One hundred sixteen clones were developed in house, and the remainder originated from the Wellcome Trust Sanger Institute. All clones were spotted at least in duplicate on the array.
Study Samples and Sample Preparation for aCGH Experiment
Seven hundred seventy unrelated patients with CD who are followed at the University Hospital Leuven and 345 healthy control subjects were included for the aCGH experiment. Diagnosis of CD was based on accepted clinical, endoscopic, radiologic, and histologic criteria. 15, 16 All individuals were of European origin. Disease location was recorded according to the Montreal classification. 17 Of the CD patients, 315 (40.9%) were male and 455 (59.1%) were female; of the healthy control subjects, 164 (47.5%) were male and 181 (52.5%) were female. Two hundred seventy CD patients (35.1%) had ileal (L1), 85 (11.0%) had colonic (L2), and 415 (53.9%) had ileocolonic (L3) disease location. The median age at diagnosis was 24 years (interquartile range [IQR], 18-30 years). DNA was extracted from venous blood using a salting-out technique, 18 and stored at 2808C. DNA was diluted and concentration measured using NanoDrop (Thermo Scientific, Wilmington, DE).
We showed that BAC-based arrays can readily detect 5% mosaicism when up to 30 successive clones are involved, and local differences including single clones can detect a 20% mosaicism. 19, 20 Therefore, we decided to cost-effectively pool patient DNA and control DNA for the aCGH experiment. We pooled DNA from 5 CD patients, each patient in a pool being of identical sex and disease location. Per patient pool, a random 5-sample control pool was put together, closely matched to the corresponding patient pool based on sex and age. To ensure that the pools are as homogeneous as possible, we constructed pools using the R package optMatch. 21 Control subjects could be reused in different pools but never in the same pool. Each control was used a median of 2 times (range, 1-9). A sex mismatch was never allowed, whereas the age difference in each matched pair was minimized (see Figure, Supplemental Digital Content 1, http://links.lww.com/IBD/B152). Matches were optimized using the Mahalanobis distance between patients and control subjects. Next, each case-control pair was assigned to a sample pool, based on location, sex, and a minimized age difference within the sample set, using a PAM clustering approach. We checked the resulting pools using box plots of age within each pool, stratified for location and sex (see Figure, Supplemental Digital Content 1, http://links.lww.com/IBD/B152). In total, we assembled 17 colon-only pools (5 male and 12 female), 54 ileum-only pools (27 male and 27 female), and 83 ileocolonic pools (31 male and 52 female).
Array Comparative Genomic Hybridization Experiment
An aCGH was performed as described previously by Vermeesch et al. 22 In brief, 150 ng genomic DNA from the patient pool and 150 ng of the matched control pool were differentially labeled by random priming with Cy3-dCTP and Cy5-dCTP (Amersham, GE Healthcare Life Sciences, Little Chalfont, UK) and cohybridized to the array overnight at 378C in a humid chamber. Hybridized arrays were washed and scanned using an Agilent Microarray Scanner (Agilent Technologies, Santa Clara, CA). Image data were extracted using Agilent Feature Extraction software, and the data were analyzed using Agilent CGH analytics software. Self-hybridization was performed to test for clonespecific variability, and direct and dye swap assays were performed for each pool combination.
Quality Control and Data Analysis
We rejected 1 array after failing laboratory quality control and excluded 84 spots with a clone length ,600 bases. Next, we excluded spots having a lower intensity than twice the median autosomal background from the analysis. The median rejected proportion was 3.5% for the green channel and 2.5% for the red channel (see Figure, Supplemental Digital Content 2, http://links.lww.com/IBD/B153). We then subtracted background intensity from foreground intensity, 19 after which we used 2-dimensional loess smoother to correct for spatial anomalies. We assessed preprocessing results using MA plots. 23 We averaged the intensity ratio per clone if 2 spots were available; otherwise we considered the available one as the measurement. We deleted a further 11 clones because they passed the quality control on less than 3 arrays or because they could not be mapped.
We summarized the results by averaging the log 2 ratio for each clone. If in the different pools we repeatedly detect either below or above average intensity ratios for a particular locus, this would indicate a lower or higher copy number of this locus (see Table, Supplemental Digital Content 3, http://links.lww.com/IBD/B154). We heuristically defined outlying clones as those with a ratio higher or lower than 3 standard deviations away from the mean (20.13 . ratio . 0.13) (see Figure, Supplemental Digital Content 4, http://links.lww.com/IBD/B155). Clones were annotated using Ensembl release 54. 24 Data analysis was done using R (http://www.R-project.org/).
Validation and Replication Using Quantitative Real-Time PCR
We performed 3 TaqMan real-time PCR copy number assays, with probes specifically targeted to C4A (Hs07226349_cn), C4B (Hs07226350_cn), or C4L (QBLnoCOX_CCSIZO) (Life Technologies Corporation, Foster City, CA). 25, 26 Validation samples included the individual patients and control subjects as used for aCGH, and an independent replication data set consisting of 1117 CD patients and 687 healthy control subjects from 3 other Belgian IBD centers (Liège University Hospital, Ghent University Hospital, and Brussels Erasme Hospital; Table 1 ). Diagnosis of CD was based on accepted clinical, endoscopic, radiologicl, and histological criteria. 15, 16 All individuals were of European origin. Four replicates of each sample were amplified with the ABI7500 FAST (Life Technologies) starting from 20 ng DNA in a 20 mL reaction, according to manufacturer's instructions. RNAse-P was used as reference gene for relative quantification. Each 96-well plate contained negative control subjects (no DNA) and 2 positive control subjects (calibrator samples). Two independent runs were performed on samples that showed aberrant fold differences. Data were analyzed with the Copy Caller software version 1.0 from Life Technologies. We calculated total C4 copy number as the sum of the C4A and C4B copy number, and C4S copy number as total C4 minus C4L copy number. As an additional validation, the C4L copy number had to be smaller than C4A and C4B combined. Differences in copy number distribution between CD patients and healthy control subjects were tested with the Wilcoxon's test using R. Graphs were plotted using R.
Principal Components and HLA Data
A subset of 1540 CD patients and 900 control subjects were genotyped using immunochip in the context of the IIBDGC immunochip project. 6 For these individuals, principal components (PCs) were available to account for population structure in the association analyses. Association tests were performed on each C4 isotype (C4L, C4S, C4A, C4B, and total C4) conditional on the first 5 PCs in R.
High-density SNP data in the HLA region and imputed HLA alleles and amino acids were available in a subset of 1404 CD patients and 881 healthy control subjects, through the IIBDGC MHC project. 27 Correlation of C4 copy number with HLA SNPs, alleles, and amino acids was tested, and conditional logistic regression analysis was performed in R.
Determination of C4 Levels in Serum
We measured C4 serum levels in a subset of 60 CD patients and 116 healthy control subjects with nephelometry on an Immage instrument (Beckman Coulter, Fullerton, CA), at the Laboratory Medicine Department of the UZ Leuven. Serum levels were compared between cases and control subjects with Mann-Whitney U in R. Correlation of C4 serum levels with copy number was tested with regression analysis in R. We included case-control status and an interaction term for copy number and status to test for differential effects in cases and control subjects.
Ethical Considerations
The ethical boards of each separate recruiting institution approved for the study (approval number B322201213950/ S53684 for University Hospital Leuven). Informed consent was obtained from all participants. All DNA samples and data in this study were handled anonymously.
RESULTS
Array Comparative Genomic Hybridization Identifies Several CNV Regions of Potential Interest in CD
After quality control, we had 3853 clones available for further analysis. The summary statistic for each clone (mean log 2 ratio) is given in Table, Supplemental Digital Content 3, http://links.lww.com/IBD/B154. A negative log 2 ratio represents a lower copy number in CD patients compared with healthy control subjects, whereas a positive ratio represents a higher copy number in CD patients compared with control subjects. One clone (RP11-758F23) had a positive outlying ratio of .0.13 (see Table 2 lists the 20 clones with lowest negative mean log 2 ratios. Five of these overlap with known IBD susceptibility loci, as indicated in Table 2 . 6 The clone with the lowest ratio (RP1-34F7) is, together with 2 other top 10 clones (RP11-598J9 and RP11-427G15), is located on chromosome 6p21 in the central MHC region (Fig. 1) . Another 3 overlapping top 20 clones (RP11-12F9, RP13-628D17, CTD-2129N23) are located on chromosome 10q24, encompassing HIF1AN and PAX2. One clone (RP13-650G11) overlapped with the MUC3A/B gene on chromosome 7q22.
Independent Replication Confirms Complement C4 as a New Susceptibility Gene for CD
We further focused on the region on chromosome 6p21. The deviating clones overlapped with the multiallelic copy number variable "RCCX" locus, which is named after the genes STK19 (serine/threonine kinase 19; formerly RP), C4 (complement component 4), CYP21 (steroid 21-hydroxylase), and TNX (tenascin-X). C4 is known to be copy number variable and can code for either a C4A or a C4B isotype protein. 28 For both C4A and C4B, the size varies between long (C4L) and short (C4S) depending on the presence or absence of the endogenous retroviral sequence HERV-K (C4). 29 We used different quantitative PCR (qPCR) assays with probes specifically targeting C4A, C4B, or C4L, to first test if individual CD patients from the aCGH experiment differed in C4 copy number compared with healthy control subjects. Copy number frequencies for total C4, C4A, C4B, C4L, and C4S are given in Table 3 . They were similar to those previously described for a German control population. 25 Raw genotype counts for all samples are given in http://links.lww.com/IBD/B156. The pattern of C4L copy number distribution in patients differed significantly from that in healthy control subjects, with a shift toward a lower copy number for CD patients compared with control subjects (P ¼ 2.66 · 10 202 ). C4S copy number also differed significantly between patients and control subjects (P ¼ 3.37 · 10 202 ). Total C4, C4A, and C4B copy number distribution did not differ between CD patients and healthy control subjects. We replicated these findings in an additional independent 1117 CD patients and 687 healthy control subjects from 3 other Belgian IBD centers (Table 1 for details on the samples, Table 3 for copy number frequencies, and see Table, Supplemental Digital Content 5, http://links.lww.com/IBD/B156 for genotype counts for all samples), where we also saw a significant shift toward a higher C4S copy number in CD patients versus healthy control subjects (P ¼ 1.15 · 10 202 ). C4L copy numbers were also shifted toward a lower number in CD patients compared with control subjects, but this was not significant (P ¼ 6.91 · 10 202 ). In the combined data set of 1802 CD patients and 1000 healthy control subjects, both C4L and C4S copy number were significantly different between CD patients and healthy control subjects (P ¼ 5.01 · 10 203 and P ¼ 9.11 · 10 204 ; Fig. 2A, B) . We did not see significant differences for C4A, C4B, or total C4 in the replication or combined cohort ( Fig. 2C-E) . For none of the C4 gene variants, there was a significant association with disease Correlation of C4 Copy Number with HLA SNPs, Alleles, and Amino Acids
Given the location of C4 within the MHC region, we checked the level of correlation with surrounding SNPs and class I and II HLA alleles and amino acids. The overall level of correlation between C4 copy numbers and HLA SNPs/alleles was very low (median r 2 linear_regression ¼ 3.89 · 10 203 ; IQR, 5.64 · 10 203 to 1.68 · 10 203 ). The IIBDGC MHC project implicated 8 HLA class II alleles and 7 HLA class I alleles in CD, with a primary role for HLA-DRB1*01:03. We performed conditional logistic regression analysis for C4 copy number and these 15 independently associated HLA class I and II alleles. Table 4 
Differential Impact of C4 Copy Number in CD Patients Compared with Healthy Control Subjects
To see if C4 copy numbers correlated with C4 serum levels in CD patients and healthy control subjects, we measured C4 serum levels in both the groups. C4 serum concentrations ranged from 0.15 to 0.61 g/L in CD patients and from 0.12 to 0.75 g/L in healthy control subjects and were similar between both the groups (medianhealthy_controls ¼ 0.32; IQR; 0.26-0.42; median CD ¼ 0.33; IQR, 0.28-0.40; P ¼ 4.51 · 10 201 ; Fig. 3A) . However, C4 serum levels were clearly related to the C4 copy number with a higher copy number associated with higher serum levels (Fig. 3B-D) . But this relationship differed for patients and control subjects: a regression model including C4 copy number, an indicator for patient status, and their interaction term showed that higher copy numbers lead to higher serum concentrations in control subjects compared with CD patients (adjusted R 2 ¼ 0.26; P , 0.001).
DISCUSSION
Copy number variants have been predicted to have an important role in genetic susceptibility to common disease, and several CNV associations have been described. 10 This genome-wide CNV analysis found several CNV regions of potential interest in CD pathogenesis. We focused on the CNV association on chromosome 6p21 in the MHC region and found that low copy numbers of the C4L and high copy numbers of the C4S gene variants of complement component C4 are risk factors for CD. Complement component C4 copy numbers are also associated with other immune diseases: low C4 copy numbers are risk factors for systemic lupus erythematosus 28, 30 and an increased frequency of C4B deficiency is seen in rheumatoid arthritis. 31 Complement component C4 is essential for the activation of the classical and lectin complement pathways and as such, an important effector protein of the immune system. The complement pathway is involved in the clearance of immune complexes and in cytolysis or neutralization of invading microbes. 32, 33 The 2 C4 isotypes, C4A and C4B, share .99% amino acid sequence identity and differ in only 5 bp in a 17-bp span. C4A proteins take part in removing immune complexes, whereas C4B proteins are active in the defense against intruders. 33, 34 The exact function of C4L compared with C4S is not clear, but it was shown that C4L confers protection against exogenous retroviral attacks. 35, 36 We observed a differential effect of total C4 copy number on C4 serum levels, where higher copy numbers led to higher serum concentrations in control subjects than in patients.
We found only relatively low levels of correlation between C4 copy number with surrounding SNPs and class I and II HLA alleles and amino acids. A previous study by Fernando et al 37 looking at the correlation between complement C4 copy number and surrounding SNPs, and integrating HLA-DRB1 allele data, in the HapMap CEU cohort and the 1958 British Birth cohort subjects also found only moderate levels of correlation and thus do not support the use of SNP genotypes as proxies for complement C4 copy number. Importantly, C4L and C4S remained significantly associated with CD when conditioning on all known associated HLA alleles. Of the other 20 BAC clones with lowest mean log 2 ratios, 3 were located on chromosome 10q24, encompassing HIF1AN and PAX2, within 1 Mb of a known susceptibility locus. 6 Clone RP11-710A19, overlapping with the most 3 0 of these clones (RP11-12F9), had a mean log 2 ratio of 20.11. PAX2 is expressed in a subset of lymphocytes 38 and represses human b-defensin1 expression. 39 Therefore, it will be interesting to further investigate this region, the more because a higher resolution CNV region as defined by Conrad et al 40 is situated in this region. One of the top 20 clones overlaps with the MUC3A/B gene on chromosome 7q22, a known IBD susceptibility locus. 6 The adjacent clone RP5-1059M17 had a mean log 2 ratio of 20.11. MUC3 is found to be less expressed in ileal mucosa of CD patients compared with healthy control subjects. 41 The MUC3 gene contains long stretches of tandem repeats. Rare variable number of tandem repeats in MUC3 are associated with ulcerative colitis. 42 The second FIGURE 3. C4 serum levels in CD patients and healthy control subjects (a). C4 levels broken down by C4 copy number in all samples (b), healthy control subjects (c) and CD patients (d).
ranked clone (RP5-1050D4, mean log 2 ¼ 20.18) is located on chromosome 17p13, overlapping with among others SLC25A11, SPAG7, KIF1C, and ENO3. This region is prone to deletions and translocations in, for example, Asperger syndrome patients 43 and cancer patients. 44 SLC25A11, one of the genes in this region, interacts with ATG16L1-a known CD susceptibility gene-leading to IL1B secretion and antibacterial autophagy. 45 RP5-1005L2 and RP11-424K17 (rank 10 and 19) overlap with a known IBD susceptibility locus. 6 Different studies show gains and losses in these regions. 9, 40, 46, 47 It remains to be determined if and how these predispose to CD.
Some studies showed an association of b-defensin 2 (DEFB4) copy number on chromosome 8 with CD: a lower copy number was seen in colonic CD patients compared with healthy control subjects, 48 but also an elevated DEFB4 copy number was seen in CD, irrespective of intestinal location. 49 Other studies failed to show an association between DEFB4 copy number and CD. 14, 50 One clone from the BAC array overlaps with the DEFB4 location on chromosome 8 (RP11-739E3) but with a mean log 2 ratio of 20.004 does not show any evidence for differential copy numbers in cases versus controls in this study. Four BAC clones (RP11-263K13, RP11-678D15, RP13-511L2, and CTD2380M22) overlapped with the known IRGM 20-kb deletion polymorphism. 13 None of these showed a deviating mean log 2 ratio. The CD-associated CNV region on chromosome 17 (CNVR7113.6) was not covered in the aCGH. 14 The fact that we could not replicate the known CD-associated CNV regions in the aCGH might be explained by the low resolution of the aCGH compared with the size of the known CNVs. The 4 clones overlapping with the IRGM deletion, for example, have a length range of 83.4 to 159.9 kb, whereas the IRGM deletion itself is 20 kb.
We acknowledge that our study has some limitations. We used BAC arrays for the CNV scan, which have a lower resolution than oligonucleotide arrays. We also lost some resolution by using a pooling strategy for the samples. Another limitation of this study is that technically it is very difficult to define the exact copy number of multiallelic CNVs as for the C4 gene. Advantages and disadvantages of different methods are described in various studies. 26, 51, 52 We used real-time qPCR because it has a high sensitivity and throughput. However, qPCR results can be influenced by differential sample preparation, storage conditions, and DNA degradation. In addition, because qPCR rounds data to the nearest integer ("binning"), copy numbers can be misscored by several copies. We performed 4 replicates for each sample, which were repeated when not identical. As an additional validation, the C4L copy number had to be smaller than C4A and C4B combined. Another limitation of the qPCR method, instead of, for example, Southern blot techniques, is that we could not determine the precise localization and order of the long and short C4 genes and the C4A and C4B genes in multimodular RCCX haplotypes. The RCCX segment can be present up to 4 times in the haploid genome, 53, 54 and the precise localization and order of C4A/C4B and C4S/C4L genes within the multimodular RCCX segments might determine the association instead of the discrete C4 copy number. RCCX modular variations/haplotypes have indeed been associated with disease. 28, 30, 54 Our study identified complement component C4 as a new susceptibility gene for CD, and we provide evidence for the complement system as an important contributor to CD pathogenesis. Also, we shed light on the MHC association observed in CD: in addition to the often studied class I and class II HLA SNPs, alleles, and amino acids, we show association of the class III HLA antigen C4 with CD.
